Literature DB >> 28450224

Pinocembrin ex vivo preconditioning improves the therapeutic efficacy of endothelial progenitor cells in monocrotaline-induced pulmonary hypertension in rats.

Lamiaa A Ahmed1, Sherine M Rizk2, Shohda A El-Maraghy3.   

Abstract

Pulmonary hypertension is still not curable and the available current therapies can only alleviate symptoms without hindering the progression of disease. The present study was directed to investigate the possible modulatory effect of pinocembrin on endothelial progenitor cells transplanted in monocrotaline-induced pulmonary hypertension in rats. Pulmonary hypertension was induced by a single subcutaneous injection of monocrotaline (60mg/kg). Endothelial progenitor cells were in vitro preconditioned with pinocembrin (25mg/L) for 30min before being i.v. injected into rats 2weeks after monocrotaline administration. Four weeks after monocrotaline administration, blood pressure, electrocardiography and right ventricular systolic pressure were recorded. Rats were sacrificed and serum was separated for determination of endothelin-1 and asymmetric dimethylarginine levels. Right ventricles and lungs were isolated for estimation of tumor necrosis factor-alpha and transforming growth factor-beta contents as well as caspase-3 activity. Moreover, protein expression of matrix metalloproteinase-9 and endothelial nitric oxide synthase in addition to myocardial connexin-43 was assessed. Finally, histological analysis of pulmonary arteries, cardiomyocyte cross-sectional area and right ventricular hypertrophy was performed and cryosections were done for estimation of cell homing. Preconditioning with pinocembrin provided a significant improvement in endothelial progenitor cells' effect towards reducing monocrotaline-induced elevation of inflammatory, fibrogenic and apoptotic markers. Furthermore, preconditioned cells induced a significant amelioration of endothelial markers and cell homing and prevented monocrotaline-induced changes in right ventricular function and histological analysis compared with native cells alone. In conclusion, pinocembrin significantly improves the therapeutic efficacy of endothelial progenitor cells in monocrotaline-induced pulmonary hypertension in rats.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Endothelial progenitor cells; Monocrotaline; Pinocembrin; Pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28450224     DOI: 10.1016/j.bcp.2017.04.024

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  The Prophylactic Effect of Pinocembrin Against Doxorubicin-Induced Cardiotoxicity in an In Vitro H9c2 Cell Model.

Authors:  Nonhlakanipho F Sangweni; Malebogo Moremane; Sylvia Riedel; Derick van Vuuren; Barbara Huisamen; Lawrence Mabasa; Reenen Barry; Rabia Johnson
Journal:  Front Pharmacol       Date:  2020-08-05       Impact factor: 5.810

2.  Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review.

Authors:  Colin M Suen; Duncan J Stewart; Joshua Montroy; Christopher Welsh; Brendan Levac; Neil Wesch; Alexander Zhai; Dean Fergusson; Lauralyn McIntyre; Manoj M Lalu
Journal:  Stem Cell Res Ther       Date:  2019-03-06       Impact factor: 6.832

3.  The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease.

Authors:  Hong-Xiao Sun; Guo-Ju Li; Zhan-Hui Du; Zhen Bing; Zhi-Xian Ji; Gang Luo; Si-Lin Pan
Journal:  BMC Pediatr       Date:  2019-12-17       Impact factor: 2.125

Review 4.  Importance of Cx43 for Right Ventricular Function.

Authors:  Kerstin Boengler; Susanne Rohrbach; Norbert Weissmann; Rainer Schulz
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 5.  Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension.

Authors:  France Dierick; Julien Solinc; Juliette Bignard; Florent Soubrier; Sophie Nadaud
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

6.  Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature.

Authors:  Eduardo Vázquez-Garza; Judith Bernal-Ramírez; Carlos Jerjes-Sánchez; Omar Lozano; Edgar Acuña-Morín; Mariana Vanoye-Tamez; Martín R Ramos-González; Héctor Chapoy-Villanueva; Luis Pérez-Plata; Luis Sánchez-Trujillo; Guillermo Torre-Amione; Alicia Ramírez-Rivera; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2020-02-03       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.